Hee-Won Jung, So Jin Park, Hoyol Jhang, Kyunik Park, Jiyeon Baek, Mirinae Lee, Seul-gi Han, Woo-Youn Kim, Dahye Kim, Ji Eun Yun, Sun-wook Kim
{"title":"潜在不适当用药对老年人残疾和死亡率的影响:韩国全国人口为基础的研究","authors":"Hee-Won Jung, So Jin Park, Hoyol Jhang, Kyunik Park, Jiyeon Baek, Mirinae Lee, Seul-gi Han, Woo-Youn Kim, Dahye Kim, Ji Eun Yun, Sun-wook Kim","doi":"10.1093/gerona/glaf045","DOIUrl":null,"url":null,"abstract":"Background Potentially Inappropriate Medications (PIMs) increase the risk of adverse health outcomes in older adults. However, the long-term effects of PIMs, particularly considering frailty and polypharmacy, remain unclear. Methods We analyzed data from the National Health Insurance Service and the National Screening Program for Transitional Ages (NSPTA) in Korea, including individuals aged 66 who participated between 2015 and 2016. Participants were categorized into PIM and No PIM groups based on prescriptions, with frailty index calculated from NSPTA results. Outcomes were tracked over 6.77 years. The primary outcome was disability; secondary outcomes included all-cause mortality and a composite endpoint of death or disability. The association between PIM and adverse outcomes was evaluated using Cox proportional hazard models. Results A total of 564,036 individuals were included. During follow-up, 10,735 (1.9%) developed disabilities, and 17,887 (3.1%) died. The PIM group (64.4%) showed higher risks of disability (2.3% vs. 1.2%) and mortality (3.6% vs. 2.4%) compared to the No PIM group (P < 0.001). The composite outcome was also more frequent in the PIM group (5.3%) compared to the No PIM group (3.2%) (P < 0.001). PIM use was associated with increased risks of disability (HR 1.22 [95% CI 1.16, 1.28]), mortality (HR 1.15 [95% CI 1.11, 1.19]), and the composite outcome (HR 1.16 [95% CI 1.13, 1.20]), even after adjusting for frailty and polypharmacy. Furthermore, as the number of PIMs increased (0, 1-2, 3-4, ≥5), the risks of disability, mortality, and the composite outcome also significantly increased (all P < 0.001). Conclusion PIM use in older adults raises risk of disability and mortality, even after adjusting to frailty and polypharmacy, and the impact grows with the number of PIMs prescribed.","PeriodicalId":22892,"journal":{"name":"The Journals of Gerontology Series A: Biological Sciences and Medical Sciences","volume":"53 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Potentially Inappropriate Medication on Disability and Mortality in Older Adults: Nationwide Population-Based Study in Korea\",\"authors\":\"Hee-Won Jung, So Jin Park, Hoyol Jhang, Kyunik Park, Jiyeon Baek, Mirinae Lee, Seul-gi Han, Woo-Youn Kim, Dahye Kim, Ji Eun Yun, Sun-wook Kim\",\"doi\":\"10.1093/gerona/glaf045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Potentially Inappropriate Medications (PIMs) increase the risk of adverse health outcomes in older adults. However, the long-term effects of PIMs, particularly considering frailty and polypharmacy, remain unclear. Methods We analyzed data from the National Health Insurance Service and the National Screening Program for Transitional Ages (NSPTA) in Korea, including individuals aged 66 who participated between 2015 and 2016. Participants were categorized into PIM and No PIM groups based on prescriptions, with frailty index calculated from NSPTA results. Outcomes were tracked over 6.77 years. The primary outcome was disability; secondary outcomes included all-cause mortality and a composite endpoint of death or disability. The association between PIM and adverse outcomes was evaluated using Cox proportional hazard models. Results A total of 564,036 individuals were included. During follow-up, 10,735 (1.9%) developed disabilities, and 17,887 (3.1%) died. The PIM group (64.4%) showed higher risks of disability (2.3% vs. 1.2%) and mortality (3.6% vs. 2.4%) compared to the No PIM group (P < 0.001). The composite outcome was also more frequent in the PIM group (5.3%) compared to the No PIM group (3.2%) (P < 0.001). PIM use was associated with increased risks of disability (HR 1.22 [95% CI 1.16, 1.28]), mortality (HR 1.15 [95% CI 1.11, 1.19]), and the composite outcome (HR 1.16 [95% CI 1.13, 1.20]), even after adjusting for frailty and polypharmacy. Furthermore, as the number of PIMs increased (0, 1-2, 3-4, ≥5), the risks of disability, mortality, and the composite outcome also significantly increased (all P < 0.001). Conclusion PIM use in older adults raises risk of disability and mortality, even after adjusting to frailty and polypharmacy, and the impact grows with the number of PIMs prescribed.\",\"PeriodicalId\":22892,\"journal\":{\"name\":\"The Journals of Gerontology Series A: Biological Sciences and Medical Sciences\",\"volume\":\"53 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journals of Gerontology Series A: Biological Sciences and Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/gerona/glaf045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journals of Gerontology Series A: Biological Sciences and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/gerona/glaf045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:潜在不适当药物(PIMs)会增加老年人不良健康结局的风险。然而,pim的长期影响,特别是考虑到虚弱和多药,仍然不清楚。方法我们分析了来自韩国国民健康保险服务和国家过渡年龄筛查计划(NSPTA)的数据,包括2015年至2016年参加的66岁个人。根据处方将参与者分为PIM组和无PIM组,并根据NSPTA结果计算虚弱指数。结果被跟踪了6.77年。主要结局是残疾;次要结局包括全因死亡率和死亡或残疾的复合终点。使用Cox比例风险模型评估PIM与不良结局之间的关系。结果共纳入564,036人。随访期间,10735例(1.9%)出现残疾,17887例(3.1%)死亡。与无PIM组相比,PIM组(64.4%)表现出更高的残疾风险(2.3%对1.2%)和死亡率(3.6%对2.4%)(P <;0.001)。与无PIM组(3.2%)相比,PIM组(5.3%)的复合结局也更频繁(P <;0.001)。使用PIM与致残风险增加(HR 1.22 [95% CI 1.16, 1.28])、死亡率(HR 1.15 [95% CI 1.11, 1.19])和综合结局(HR 1.16 [95% CI 1.13, 1.20])相关,即使在调整虚弱和多药治疗后也是如此。此外,随着pim数量的增加(0、1-2、3-4、≥5),致残、死亡和综合结局的风险也显著增加(P <;0.001)。结论老年人使用PIM会增加致残和死亡的风险,即使在调整到虚弱和多药后也是如此,而且影响随着PIM的使用数量而增加。
Impact of Potentially Inappropriate Medication on Disability and Mortality in Older Adults: Nationwide Population-Based Study in Korea
Background Potentially Inappropriate Medications (PIMs) increase the risk of adverse health outcomes in older adults. However, the long-term effects of PIMs, particularly considering frailty and polypharmacy, remain unclear. Methods We analyzed data from the National Health Insurance Service and the National Screening Program for Transitional Ages (NSPTA) in Korea, including individuals aged 66 who participated between 2015 and 2016. Participants were categorized into PIM and No PIM groups based on prescriptions, with frailty index calculated from NSPTA results. Outcomes were tracked over 6.77 years. The primary outcome was disability; secondary outcomes included all-cause mortality and a composite endpoint of death or disability. The association between PIM and adverse outcomes was evaluated using Cox proportional hazard models. Results A total of 564,036 individuals were included. During follow-up, 10,735 (1.9%) developed disabilities, and 17,887 (3.1%) died. The PIM group (64.4%) showed higher risks of disability (2.3% vs. 1.2%) and mortality (3.6% vs. 2.4%) compared to the No PIM group (P < 0.001). The composite outcome was also more frequent in the PIM group (5.3%) compared to the No PIM group (3.2%) (P < 0.001). PIM use was associated with increased risks of disability (HR 1.22 [95% CI 1.16, 1.28]), mortality (HR 1.15 [95% CI 1.11, 1.19]), and the composite outcome (HR 1.16 [95% CI 1.13, 1.20]), even after adjusting for frailty and polypharmacy. Furthermore, as the number of PIMs increased (0, 1-2, 3-4, ≥5), the risks of disability, mortality, and the composite outcome also significantly increased (all P < 0.001). Conclusion PIM use in older adults raises risk of disability and mortality, even after adjusting to frailty and polypharmacy, and the impact grows with the number of PIMs prescribed.